[1] |
Battipaglia I, Lanza GA. The Autonomic Nervous System of the Heart[M]// Autonomic Innervation of the Heart. Berlin, Heidelberg: Springer, 2015: 1-12.
|
[2] |
Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications[J]. J Am Coll Cardiol, 2009, 54(19): 1747-62. doi: 10.1016/j.jacc.2009.05.015
|
[3] |
Zipes DP. Heart-brain interactions in cardiac arrhythmias: role of the autonomic nervous system[J]. Cleve Clin J Med, 2008, 75(Suppl 2): S94-6.
|
[4] |
Olshansky B, Sabbah HN, Hauptman PJ, et al. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy[J]. Circulation, 2008, 118(8): 863-71. doi: 10.1161/CIRCULATIONAHA.107.760405
|
[5] |
Brack KE, Winter J, Ng GA. Mechanisms underlying the autonomic modulation of ventricular fibrillation initiation-tentative prophylactic properties of vagus nerve stimulation on malignant arrhythmias in heart failure[J]. Heart Fail Rev, 2013, 18(4): 389-408. doi: 10.1007/s10741-012-9314-2
|
[6] |
Le Guludec D, Delforge J, Syrota A, et al. In vivo quantification of myocardial muscarinic receptors in heart transplant patients[J]. Circulation, 1994, 90(1): 172-8. doi: 10.1161/01.CIR.90.1.172
|
[7] |
Le Guludec D, Cohen- Solal A, Delforge J, et al. Increased myocardial muscarinic receptor density in idiopathic dilated cardiomyopathy: an in vivo PET study[J]. Circulation, 1997, 96 (10): 3416-22. doi: 10.1161/01.CIR.96.10.3416
|
[8] |
Bucerius J, Joe AY, Schmaljohann J, et al. Feasibility of 2-deoxy-2-[18F]fluoro- D- glucose-A85380- PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo[J]. Clin Res Cardiol, 2006, 95(2): 105-9. doi: 10.1007/s00392-006-0342-6
|
[9] |
Boutagy NE, Sinusas AJ. Recent advances and clinical applications of PET cardiac autonomic nervous system imaging[J]. Curr Cardiol Rep, 2017, 19(4): 33. doi: 10.1007/s11886-017-0843-0
|
[10] |
Wang JQ, Miller MA, Mock BH, et al. Facile synthesis and PET imaging of a novel potential heart acetylcholinesterase tracer N-[11C] methyl-3-[[(dimethylamino)carbonyl]oxy]-2-(2', 2'-diphenylpropio-noxymethyl)pyridinium[J]. Bioorg Med Chem Lett, 2005, 15(20): 4510-4. doi: 10.1016/j.bmcl.2005.07.034
|
[11] |
Pain CD, O'Keefe GJ, Ackermann U, et al. Human biodistribution and internal dosimetry of 4-[18F]fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart[J]. EJNMMI Res, 2020, 10(1): 61. doi: 10.1186/s13550-020-00641-1
|
[12] |
Pauza DH, Saburkina I, Rysevaite K, et al. Neuroanatomy of the murine cardiac conduction system: a combined stereomicroscopic and fluorescence immunohistochemical study[J]. Auton Neurosci, 2013, 176(1-2): 32-47. doi: 10.1016/j.autneu.2013.01.006
|
[13] |
De Vos F, Santens P, Vermeirsch H, et al. Pharmacological evaluation of[11C]donepezil as tracer for visualization of acetylcholinesterase by PET[J]. Nucl Med Biol, 2000, 27(8): 745-7. doi: 10.1016/S0969-8051(00)00166-9
|
[14] |
Gjerløff T, Jakobsen S, Nahimi A, et al. In vivo imaging of human acetylcholinesterase density in peripheral organs using 11C-donepezil: dosimetry, biodistribution, and kinetic analyses[J]. J Nucl Med, 2014, 55(11): 1818-24. doi: 10.2967/jnumed.114.143859
|
[15] |
Gjerløff T, Fedorova T, Knudsen K, et al. Imaging acetylcho-linesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET[J]. Brain, 2015, 138(3): 653-63. doi: 10.1093/brain/awu369
|
[16] |
Watabe T, Naka S, Ikeda H, et al. Distribution of intravenously administered acetylcholinesterase inhibitor and acetylcholinesterase activity in the adrenal gland: 11C-donepezil PET study in the normal rat[J]. PLoS One, 2014, 9(9): e107427. doi: 10.1371/journal.pone.0107427
|
[17] |
Sullivan JP, Donnelly-Roberts D, Briggs CA, et al. A-85380[3-(2(S)-azetidinylmethoxy) pyridine]: In Vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand[J]. Neuropharmacology, 1996, 35(6): 725-34. doi: 10.1016/0028-3908(96)84644-2
|
[18] |
Dollé F. Fluorine-18-labelled fluoropyridines: advances in radio- pharmaceutical design[J]. Curr Pharm Des, 2005, 11(25): 3221-35. doi: 10.2174/138161205774424645
|
[19] |
Dollé F, Valette H, Bottlaender M, et al. Synthesis of 2‐[18F] fluoro-3-[2(S)‐2‐azetidinylmethoxy] pyridine, a highly potent radioligand for in vivo imaging central nicotinic acetylcholine receptors[J]. J Labelled Compd Rad, 1998, 41(5): 451-63. doi: 10.1002/(SICI)1099-1344(199805)41:5<451::AID-JLCR111>3.0.CO;2-R
|
[20] |
Dollé F, Dolci L, Valette H, et al. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)- 2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors[J]. J Med Chem, 1999, 42(12): 2251-9. doi: 10.1021/jm9910223
|
[21] |
Schmaljohann J, Minnerop M, Karwath P, et al. Imaging of central nAChReceptors with 2-[18F]F- A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease[J]. Appl Radiat Isot, 2004, 61 (6): 1235-40. doi: 10.1016/j.apradiso.2004.02.026
|
[22] |
Schmaljohann J, Gündisch D, Minnerop M, et al. A simple and fast method for the preparation of n. c. a. 2-[18F]F-A85380 for human use[J]. Appl Radiat Isot, 2005, 63(4): 433-5.
|
[23] |
Le Guludec D, Delforge J, Dollé F. Imaging the parasympathetic cardiac innervation with PET[M]//Autonomic Innervation of the Heart. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015: 111-135.
|
[24] |
Valette H, Syrota A, Fuseau C. Down-regulation of cardiac muscarinic receptors induced by di-isopropylfluorophosphate[J]. J Nucl Med, 1997, 38(9): 1430-3.
|
[25] |
Delforge J, Pappata S, Millet P, et al. Quantification of benzodiazepine receptors in human brain using PET, [11C] flumazenil, and a single-experiment protocol[J]. J Cereb Blood Flow Metab, 1995, 15(2): 284-300. doi: 10.1038/jcbfm.1995.34
|
[26] |
Delforge J, Le Guludec D, Syrota A, et al. Quantification of myocardial muscarinic receptors with PET in humans[J]. J Nucl Med, 1993, 34(6): 981-91.
|
[27] |
Dollé F, Hinnen F, Vaufrey F, et al. Highly efficient synthesis of[11C] Me-QNB, a selective radioligand for the quantification of the cardiac muscarinic receptors using PET[J]. J Labelled Compd Rad, 2001, 44(5): 337-45. doi: 10.1002/jlcr.460
|
[28] |
Maziere M, Berger G, Godot JM, et al. 11C-methiodide quinuclidinyl benzilate a muscarinic antagonist for in vivo studies of myocardial muscarinic receptors[J]. J Radioanal Chem, 1983, 76(2): 305-9. doi: 10.1007/BF02517595
|
[29] |
Gómez-Vallejo V, González-Esparza M, Llop J. Facile and improved synthesis of[11C]Me-QNB[J]. J Labelled Compd Rad, 2012, 55(13): 470-3. doi: 10.1002/jlcr.2979
|
[30] |
Mazzadi AN, Pineau J, Costes N, et al. Muscarinic receptor upregulation in patients with myocardial infarction: a new paradigm[J]. Circ Cardiovasc Imaging, 2009, 2(5): 365-72. doi: 10.1161/CIRCIMAGING.108.822106
|
[31] |
Hwang DR, Dence CS, McKinnon ZA, et al. Positron labeled muscarinic acetylcholine receptor antagonist: 2- and 4-[18F]fluoro-dexetimide. Syntheses and biodistribution[J]. Int J Radiat Appl Instrum B Nucl Med Biol, 1991, 18(2): 247-52. doi: 10.1016/0883-2897(91)90086-Z
|
[32] |
Rowe CC, Krishnadas N, Ackermann U, et al. PET Imaging of brain muscarinic receptors with 18F- Fluorobenzyl- Dexetimide: a first in human study[J]. Psychiatry Res Neuroimaging, 2021, 316: 111354. doi: 10.1016/j.pscychresns.2021.111354
|